Type II (IDH2 mutation) is associated with earlier onset, more severe developmental delay, higher seizure frequency and reduced life expectancy than type I (D2HGDH mutation), and ∼50 % of patients have cardiomyopathy, which is not observed in type I (Kranendijk et al 2012). The gene discussed is IDH2; the disease is cardiomyopathy.